A carregar...
Systematic review of azacitidine regimens in myelodysplastic syndrome and acute myeloid leukemia
BACKGROUND: 5-Azacitidine administered as a 7-day dosing regimen (7–0-0) is approved in high risk IPSS myelodysplastic syndrome (MDS) patients. Alternative regimens such as a 5-day (5–0-0) or 7-day with a weekend break (5–2-2) are commonly used. No randomized controlled trial has been done directly...
Na minha lista:
| Publicado no: | BMC Hematol |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BioMed Central
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5793426/ https://ncbi.nlm.nih.gov/pubmed/29435331 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12878-017-0094-8 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|